Taking stock and looking ahead: Behavioural science lessons for implementing the nonavalent human papillomavirus vaccine by Forster, AS & Waller, J
European Journal of Cancer 62 (2016) 96e102Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer.comCurrent PerspectiveTaking stock and looking ahead: Behavioural science
lessons for implementing the nonavalent human
papillomavirus vaccineAlice S. Forster*, Jo WallerHealth Behaviour Research Centre, UCL, Gower Street, London, WC1E 6BT, UKReceived 10 February 2016; received in revised form 11 April 2016; accepted 14 April 2016KEYWORDS
Papillomavirus
vaccines;
Behavioural science;
Patient acceptance of
health care;
Decision making;
Psychological
intervention* Corresponding author. Tel.: þ44 203
E-mail address: alice.forster@ucl.ac.
http://dx.doi.org/10.1016/j.ejca.2016.04.0
0959-8049/ª 2016 The Authors. Publish
licenses/by/4.0/).Abstract The development and licensing of a nonavalent human papillomavirus (HPV) vac-
cine has the potential to reduce morbidity and mortality from HPV-related cancers beyond
that of first generation HPV vaccines. However, this benefit can only be realised if the offer
of vaccination is accepted. Uptake of first generation HPV vaccines is not complete and shows
huge global variation. In addition to practical and financial challenges to optimising coverage,
behavioural issues explain a large proportion of the variance in vaccine receipt. This commen-
tary draws on the findings of over a decade of behavioural science research seeking to under-
stand uptake of first generation HPV vaccines, in order to anticipate challenges to
implement the nonavalent HPV vaccine. Challenges include distrust of combination vaccines,
uncertainty about long-term efficacy, distrust of a new and (perceived to be) untested vaccine,
cost and uncertainty regarding interchanging doses of first generation and nonavalent vaccines
and the appropriateness of revaccination. We use behavioural science theory and existing eval-
uations of interventions to increase uptake of vaccines to identify evidence-based approaches
that can be implemented by vaccine stakeholders to address parents’ concerns and maximise
uptake of the nonavalent HPV vaccine.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).108 3293.
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advancement in prevention of human papillomavirus-
related cancers
Human papillomavirus (HPV) is causally related to
cancers of the cervix uteri, penis, vulva, vagina, anus
and oropharynx. The development and worldwide
implementation of vaccines against HPV have the po-
tential to substantially reduce the burden of HPV-
related cancers. First generation HPV vaccines (biva-
lent and quadrivalent HPV vaccines) offer protection
against HPV types 16 and 18, which are known to cause
up to 80% of HPV-related cancers (depending on cancer
site) [1,2]. The quadrivalent vaccine also offers protec-
tion against HPV types 6 and 11 which cause most
anogenital warts. Vaccination is recommended to in-
dividuals aged 9 years and upwards, but works best if
administered to HPV-naive individuals and in younger
populations [3]. When the vaccines were first licensed,
three doses were recommended but subsequent evidence
suggests that two doses provide sufficient protection
among younger girls [4].
More recently, a vaccineprotectingagainst nine types of
HPVhasbeen licensed for use in theEuropeanUnion (EU)
and United States of America (USA, the nonavalent or
nine-valent vaccine) [5]. This vaccine provides protection
against five additional high-risk types which, togetherwith
HPV 16 and 18, cause around 90% of cervical cancers [6].Fig. 1. Female uptake and program delivery method of selected count
ahttps://www.gov.uk/government/uploads/system/uploads/attachment_
bhttp://www.cdc.gov/mmwr/preview/mmwrhtml/mm6429a3.htm#tab1.
chttp://www.hpvregister.org.au/research/coverage-data/HPV-Vaccinatio
dhttps://www.hpsc.ie/A-Z/VaccinePreventable/Vaccination/Immunisatio
File,15198,en.pdf.
ehttp://www.health.govt.nz/our-work/preventative-health-wellness/imm
fhttp://www.who.int/bulletin/volumes/90/8/11-097253/en/.
ghttp://www.sciencedirect.com/science/article/pii/S0264410X15007513.The vaccine may prevent an additional 4e18% of HPV-
related cancers compared to bivalent/quadrivalent vac-
cines [7] and will provide equivalent protection against
genital warts. A randomised controlled trial showed that
the nonavalent vaccine was more effective at preventing
HPV types 31, 33, 45, 52 and 58 than the quadrivalent
vaccine and was non-inferior at preventing HPV types 6,
11, 16 and 18 [5]. The proportion of clinical adverse events
was similar in the two groups, although adverse events
related to the injection site (mild/moderate pain, swelling,
redness, and itching) weremore common in the group that
received the nonavalent vaccine. Price permitting [8], it is
likely that the nonavalent vaccine will be introduced into
immunisation programs worldwide.
While the development of vaccines against HPV
represents a tremendous scientific advance, the promise
of reduced incidence of HPV-related cancers can only
be realised if the offer of vaccination is accepted.
However, uptake is sub-optimal in most countries and
shows wide global variation. With few exceptions [9], it
tends to be highest in countries with school-based
programs; for example, in Australia, uptake was 73%
for girls turning 15 in 2014 [10]. By contrast, countries
using clinic-based delivery often have lower uptake,
exemplified by the USA where only around 40% of 13-
to 17-year-old girls completed the series in 2014 [11]
(see Fig. 1). It is striking that, with the exception of
countries in South America, countries with organisedries.
data/file/487514/HPV_2014_15_ReportFinal181215_v1.1.pdf.
n-Coverage-2014.
nUptakeStatistics/HPVImmunisationUptakeStatistics/
unisation/hpv-immunisation-programme.
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be those where the burden of disease is already low. In
sub-Saharan Africa where the need is greatest, vacci-
nation is generally not available, despite the on-going
efforts of ‘Gavi, the Vaccine Alliance’. However, in
this review, we focus on maximising uptake in coun-
tries where the vaccine is offered.
In addition to the practical and financial challenges
to implementing vaccination programs and optimising
coverage, behavioural issues have been shown to
explain 40% of the variance in vaccine receipt [12].
Behavioural scientists have over a decade of experience
conducting research into uptake of first generation
HPV vaccines and can use the wealth of knowledge
gained to anticipate challenges to implement non-
avalent vaccines. Some challenges will be common to
all vaccines (e.g. practical barriers to uptake) but
others will be specific to HPV vaccination (e.g. low
perceived risk of HPV infection) or to the nonavalent
vaccine itself. In this commentary, we offer a behav-
ioural science perspective on the challenges to maxi-
mise uptake of the nonavalent vaccine. Challenges are
split into those that are psychological (the focus of
behavioural science) and those related to service de-
livery, which are often raised by participants in
behavioural science studies (Fig. 2).
2. What are the psychological challenges to vaccine
uptake?
2.1. Distrust of combination vaccines e ‘Will the
nonavalent vaccine overload the immune system?’
Studies have identified parental concern that vaccines
can damage children by overloading their immunePsychological challenges 
Distrust of combination vaccines 
Uncertainty about long-term efficacy 
Uncertainty about the safety of a new an
Service-delivery challenges 
Cost 
Interchanging vaccines and revaccination
Fig. 2. Challenges to maximise uptsystems [13], as well as worry that particular in-
gredients in vaccines make them risky for their children
[14]. Combination vaccines are considered particularly
risky for both of these reasons [13,14] as they are
perceived to contain a greater number of ingredients
mixed together, thus increasing the potency and po-
tential for side-effects. The nonavalent vaccine is not a
combination vaccine; however, parents are likely to be
aware of first generation HPV vaccines and view the
nonavalent vaccine as more complex (affording pro-
tection against nine as opposed to two or four HPV
types).
2.2. Uncertainty about long-term efficacy e ‘I’ll wait to
decide until there’s more evidence that it will protect my
daughter in her twenties’
Uncertainty about the duration of protection afforded
by first generation HPV vaccines has been a prevalent
concern, due to the relatively recent development of
the vaccines, and the scientific uncertainty about the
actual duration of protection [15] (although estimates
suggest that protection will last decades [6]). For this
reason, parents who do not expect their child to be
sexually active in the near future may be particularly
likely to delay HPV vaccination [16]. Unpublished data
from our group (Forster, Rockliffe, Waller et al.)
suggest that these parents believe that vaccination
should occur close to sexual debut to maximise the
duration of protection after potential exposure to
HPV. Concerns about duration of protection are not
limited to HPV vaccines [17]. The nonavalent vaccine
may be seen by parents as going ‘back to square one’
in terms of the evidence of long-term efficacy, as it is
newly developed.d (perceived to be) untested vaccine 
 
ake of the nonavalent vaccine.
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to be) untested vaccine e ‘They don’t know about the
long-term side-effects’
One online focus group study of parents of vaccinated
and unvaccinated girls, conducted in the USA, identified
concern about side-effects of the nonavalent vaccine [18].
Worry about possible long-term side-effects of first gen-
eration HPV vaccines is a well-established barrier to
vaccine acceptance, and centres on the lack of long-term
surveillance data due to the vaccine’s novelty [14,15].
Parents who do not expect their child to be sexually active
in the near future tend to feel they can afford to delay
vaccination until more evidence about safety is available
[19]. Parents may perceive that there is even less evidence
on long-term safety of the nonavalent vaccine.
Concerns about vaccine safety are not unique to
HPV vaccines. However, the impact of such concerns
on vaccine coverage should not be underestimated.
Pre- and post-licensing surveillance data show that
HPV vaccines are safe [5,20]. However, anecdotal re-
ports of serious adverse events have been presented in
the media, resulting in parents receiving conflicting
information. Governments have had varying degrees of
success in managing these reports. For example in the
United Kingdom (UK), a girl died shortly after
receiving the HPV vaccination, but her death was
quickly attributed to a tumour in her chest [21].
Management of the event by public health authorities
resulted in no noticeable impact on HPV vaccination
coverage in the UK [22]. Conversely, uptake in Japan
decreased significantly after the Ministry of Health
asked local health authorities to stop promoting the
vaccine following public reports of adverse events [23].
While public health officials might be able to contain
vaccine concerns among their own population, vaccine
sentiments travel globally.1 Note that these studies were conducted in countries where HPV
vaccination is covered by national health authorities or medical
insurance.3. What are the service-delivery challenges to vaccination
uptake?
3.1. Cost e ‘I can’t afford three doses of the vaccine’
Economic modelling suggests that nonavalent vaccina-
tion would be more cost-effective than quadrivalent if the
additional cost per dose did not exceed $13 [8]. Even if the
price of the nonavalent vaccine does not exceed this
threshold, where payment for vaccination is not met by
health services or medical insurance, cost is likely to
prohibit vaccine receipt for some. This is particularly the
case in developing countries, although ‘Gavi, the Vaccine
Alliance’ has facilitated HPV vaccination for many in-
dividuals. Three doses of the nonavalent vaccine are
required, compared to only two doses of first generation
vaccines, which will increase cost for those paying for
vaccination privately. Cost has previously been reportedas a concern about first generation and nonavalent vac-
cines1 [18,24] and may result in individuals starting but
not completing the vaccine series.
3.2. Interchanging vaccines and revaccination e ‘Can my
daughter have both a first generation vaccine and the
nonavalent one?’
While the nonavalent vaccine is being introduced, par-
ents whose children have had one or two doses of a first
generation HPV vaccine may query whether it is
possible to complete the series with the nonavalent one.
In addition, parents whose children have completed the
series with one of the first generation vaccines may see
the benefits of the nonavalent vaccine and consider
whether it is appropriate to revaccinate with the new
vaccine. However, there have been no studies looking at
the inter-changeability of HPV vaccines and there is
only preliminary evidence that vaccination with the
nonavalent vaccine is safe following series completion
with the quadrivalent vaccine [25]. Temporary guidance
on this issue for individuals exists [25] but clinical data
are needed to inform vaccination programs.
4. What can be done to increase uptake of the vaccine?
Where parents are given the option to choose between
first generation and nonavalent vaccines, uptake may
not fall, as parents with concerns can choose the more
established first generation alternative. However, where
choice of HPV vaccine is restricted by health insurers/
health authorities, the vaccine offered may affect up-
take. In such circumstances, vaccination stakeholders
would benefit from the insights that behavioural science
can offer about interventions for maximising uptake.
The behavioural scientist’s toolkit includes a number
of theories that have informed research seeking to un-
derstand the psychosocial factors influencing HPV vac-
cine receipt, as well as to identify targets for
interventions to increase uptake. Two key theories have
been used often in this field: the theory of planned
behaviour (TPB) [26] and the health belief model
(HBM) [27] (Figs 3 and 4). The TPB suggests that
behaviour is directly informed by behavioural intentions
and an individual’s perceived behavioural control (PBC,
whether they believe they have control over performing
the behaviour). Behavioural intentions are influenced by
a person’s attitudes, subjective norms (beliefs about
what others would want them to do and their motiva-
tion to comply with this), as well as their PBC. The
HBM suggests that six constructs influence whether a
behaviour will be performed: perceived susceptibility
Attitudes
Subjective 
norms
Perceived 
behavioural 
control
Intention Behaviour
Behavioural 
beliefs
Evaluation of 
consequences
Normative 
beliefs
Motivation to 
comply
Evaluation of 
internal and 
external 
resources
Fig. 3. Theory of planned behaviour.
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benefits and barriers to engaging in the recommended
preventive behaviour, self-efficacy (akin to PBC) and
cues to action (triggers that prompt behaviour). Given
that many of the challenges discussed relate to the
perceived costs and benefits of the nonavalent vaccine
(HBM) and individuals’ attitudes towards it (TPB),
vaccine stakeholders seeking to increase uptake of the
nonavalent vaccine may wish to consider intervening to
change constructs of the HBM and TPB as these the-
ories have been shown as a whole to predict vaccination
behaviour [12]. Additional motivators to vaccination
may be considered as targets, for example, although
smoking status is associated with HPV positivity, to our
knowledge, interventions to increase uptake of HPV
vaccination have not been directed specifically at in-
dividuals who smoke.Demographic 
variables
Age, gender etc.
Perceived 
barriers
Perceived 
benefits
Perceived 
susceptibility
Perceived 
severity
Self-efficacy
Psychological 
characteristics
E.g. personality
Fig. 4. Health bThere is evidence that some behavioural interventions
are effective at increasing uptake of HPV vaccination
[28,29] and these may be modified to address concerns
about the nonavalent vaccine. Educational interventions
aimed at both parents and adolescents have generally
not demonstrated effectiveness at increasing HPV
vaccination uptake [28] (although improvements in ad-
olescents’ attitudes towards vaccination are observed),
whereas practice- and community-based interventions
(such as reminders and school-based programs) are
likely to be more successful [29]. We also know that the
use of ‘presumptive’ communication (‘your child is due
for the HPV vaccine’) is associated with greater vaccine
acceptance compared with ‘participatory’ communica-
tion (‘what do you want to do about the HPV vaccine?’)
[30]; although debates about which of these is most
appropriate, given the need for informed consent, areCues to action
Action
elief model.
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minimise girls’ anxiety about having an injection, for
delivery in school-based programs (to avoid mass syn-
cope) [31]; however, there is not yet evidence of the ef-
ficacy of such interventions.
Vaccination stakeholders may also consider
addressing some of the concerns that parents may have
about the nonavalent vaccine. Parents’ potential con-
cerns about the safety and efficacy of the nonavalent
vaccine may be clarified by explaining what testing has
been done and why efficacy is likely to be sustained.
Long-term studies of cohorts who received the quadri-
valent vaccine have not shown any reduction in immu-
nity, suggesting that the nonavalent vaccine may also
provide long-term protection [5]. The nonavalent vac-
cine demonstrated a good safety profile and it has been
licensed for use in the USA and EU. Parents’ prefer-
ences to delay vaccination to maximise the time that
their child is protected against HPV (because they are
concerned about long-term efficacy and safety coupled
with their belief that their child will not be sexually
active soon) may be challenged by explaining that the
vaccine leads to a better immune response if delivered
when an individual is younger. Finally, where evidence
is lacking regarding the inter-changeability of HPV
vaccines and revaccination, health professionals will
need to be sufficiently prepared to answer queries.
5. Conclusions
Nonavalent HPV vaccines represent a new opportunity
to prevent HPV-related cancers. Drawing on the
evidence-base generated by behavioural science with
regard to first generation HPV vaccines, vaccination
stakeholders can anticipate parents’ concerns and be
prepared to address them. Modifying interventions that
we know are effective at improving HPV vaccination
uptake, so that they tackle concerns specific to the
nonavalent vaccine, may help to maximise uptake.
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